Adagene Inc. (ADAG)
$3.66-$0.22 (-5.64%) Today
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 23,245 | $85K |
| Grant or award | 4 | 80,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
5 Form 4 filings on record, the earliest from Aug 6, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Li Zhu - Director | Grant or award | Nonqualified Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Andy Yiu Leung Cheung - Director | Grant or award | Nonqualified Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Cuong V. Do - Director | Grant or award | Nonqualified Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Ulf Grawunder - Director | Grant or award | Nonqualified Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Peter Luo - Officer | Open-market purchase | American Depositary Shares (ADS) | 22,966 | $3.65 | $84K | |
| Peter Luo - Officer | Open-market purchase | American Depositary Shares (ADS) | 279 | $3.65 | $1K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Adagene Inc. | Officer | 40,000 | $158K | View on EDGAR | |
| GU CHUNFANG | Officer | 40,000 | $158K | View on EDGAR |
Adagene Inc. (ADAG) had 5 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for ADAG runs to 5 Form 4 filings, the earliest from 2026-08-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
2 insider purchases of ADAG were filed in the last 90 days, totaling $85K.
No insider sales of ADAG were filed in the last 90 days.
This page tracks ADAG Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ADAG to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$ADBTAdvasa Holdings, Inc.
$ADCTADC Therapeutics SA
$ADGMAdagio Medical Holdings, Inc.
$ADIGADI GLOBAL DISTRIBUTION INC.
$ADILADIAL PHARMACEUTICALS, INC.
$ADPTAdaptive Biotechnologies Corp
$ADRTAult Disruptive Technologies Corp
$ADTXAditxt, Inc.
$ADVBAdvanced Biomed Inc.
$ADXADAMS DIVERSIFIED EQUITY FUND, INC.Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.